Continuous Probabilities Identify High-Risk Patients in Hypoinflammatory Respiratory Failure

Refining Risk Stratification in Acute Respiratory Failure

Managing acute respiratory failure in the intensive care unit requires precise prognostic tools to guide complex interventions and improve survival rates. International consensus guidelines, such as the Surviving Sepsis Campaign, have established level 1 recommendations to standardize care for septic shock, yet the heterogeneous nature of critically ill populations often complicates the application of uniform treatment strategies [1, 2]. Clinical practice relies on randomized controlled trials like the Transfusion Requirements in Critical Care trial, which demonstrated that a restrictive red-cell transfusion strategy (a hemoglobin threshold of 7.0 g/dL) is at least as effective as a liberal strategy (a threshold of 10.0 g/dL) in most critically ill patients [3]. However, the quality of evidence is often limited by reporting deficiencies. For instance, the Consolidated Standards of Reporting Trials and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses were developed to address the suboptimal transparency that hinders the identification of specific patient subgroups [4, 5]. As seen in community-acquired pneumonia, where overlap with healthcare-associated pneumonia can lead to diagnostic ambiguity, moving beyond traditional binary classifications is essential for optimizing therapy in high-risk patients [6]. A recent study demonstrates how continuous probability modeling can better identify critically ill patients who require more aggressive intervention.

Limitations of Binary Inflammatory Phenotyping

The researchers sought to determine whether traditional binary classification, which divides patients into hyperinflammatory or hypoinflammatory subphenotypes, fails to account for significant clinical variation within those groups. To investigate this, the study analyzed a primary cohort of 575 critically ill adults with acute hypoxemic respiratory failure (AHRF) sourced from the Pittsburgh Acute Lung Injury Registry. To ensure the robustness of the findings, the researchers validated their results in an additional 1,134 patients across multiple diverse populations, including the EDEN trial, various COVID-19 cohorts, and the RoCI registry. This large-scale validation suggests that the observed patterns of inflammatory risk are consistent across different etiologies of respiratory failure. To quantify inflammatory status, the team utilized a parsimonious biomarker model (a simplified statistical tool that uses a minimal number of variables to predict outcomes without overfitting the data). This model incorporated levels of interleukin-6 (IL-6), soluble tumor necrosis factor receptor-1 (sTNFR-1), and bicarbonate to calculate continuous subphenotype probabilities. In traditional binary classification, a probability threshold of 0.5 is used to separate patients: those above 0.5 are labeled hyperinflammatory, while those below are labeled hypoinflammatory. In the primary cohort of 575 patients, this method classified 77 patients (13%) as hyperinflammatory and 498 patients (87%) as hypoinflammatory. The findings indicate that this binary classification obscures substantial prognostic heterogeneity, specifically among patients labeled as hypoinflammatory. While the hyperinflammatory group showed relatively uniform outcomes, the hypoinflammatory group contained a wide spectrum of risk that the binary low-inflammation label fails to capture. By treating the inflammatory state as a continuous probability rather than a simple categorical variable, clinicians may better identify high-risk individuals who currently fall just below the 0.5 threshold but still face significant mortality risks.

Hidden Mortality Risk in the Hypoinflammatory Group

The researchers focused on 90-day mortality as the primary outcome to assess the prognostic value of continuous inflammatory modeling. Among the 77 patients classified as hyperinflammatory, the study found prognostic homogeneity, meaning the risk of death remained relatively constant regardless of where a patient fell within that specific category. This group demonstrated an overall mortality of 55%, and the lack of significant variation across the group was confirmed by a p-value of 0.72 across tertiles. For the clinician, these data suggest that once a patient crosses the threshold into a hyperinflammatory state, their risk profile is consistently high and uniform. In contrast, the 498 patients in the hypoinflammatory group exhibited marked heterogeneity, revealing that the standard binary label masks a wide range of clinical outcomes. Within this group, 90-day mortality increased significantly from 19% to 31% and finally to 40% across the three probability tertiles (P < 0.001). This finding is clinically significant because it identifies a subset of patients labeled as hypoinflammatory who actually face a 40% risk of death, a figure much closer to the hyperinflammatory group than to their lower-risk hypoinflammatory peers. This suggests that the binary low-inflammation label may provide a false sense of security for a substantial portion of the patient population. To further analyze these trends, the authors utilized restricted cubic spline modeling (a statistical method used to map complex, non-linear relationships between variables without forcing them into a straight line). This analysis demonstrated a strong non-linear relationship between continuous inflammatory probabilities and mortality. Notably, the steepest increases in mortality risk occurred at probability levels below the 0.5 threshold, the very point where traditional binary classification would categorize a patient as low-risk. For the practicing physician, these data indicate that the transition from low to high risk is not a sudden jump at the 0.5 mark, but a rapid escalation that begins much earlier, potentially identifying high-risk patients who are currently excluded from subphenotype-guided clinical trials.

Clinical Trajectories and Biomarker Correlation

The continuous probability model correlates closely with established clinical indicators of disease severity. Within the hypoinflammatory group, clinical severity scores and biomarkers of immune activation increased progressively across the probability tertiles (all P < 0.001). This finding suggests that even among patients who do not meet the 0.5 threshold for hyperinflammation, those with higher probability scores exhibit a more severe clinical phenotype and a more robust immune response. For the clinician, this indicates that the continuous probability score reflects the underlying physiological burden of the disease more accurately than a simple binary classification, providing a more granular view of the patient's inflammatory state. The study also examined how these inflammatory profiles evolve over time through longitudinal sampling of 330 patients, which involves repeated biomarker measurements to track changes in a patient's condition. This analysis revealed that the direction of a patient's inflammatory trajectory is a potent predictor of survival. Among patients initially classified in the hypoinflammatory group, rising probability trajectories predicted a mortality rate between 50% and 100%. In contrast, patients in the same group with stable or declining trajectories had a predicted mortality of 16% to 40% (P < 0.001). These data highlight the importance of serial biomarker assessment. A patient who appears low risk at admission but shows an increasing inflammatory probability may actually face a prognosis as dire as those in the hyperinflammatory category. Conversely, the prognostic value of these trajectories was less pronounced in the most severely ill patients. The researchers found that hyperinflammatory patients experienced poor outcomes regardless of their probability trajectory. Unlike the hypoinflammatory group, where a declining trajectory suggested a significantly improved chance of survival, the hyperinflammatory cohort maintained a high risk of death even if their inflammatory markers showed signs of stabilization or improvement. This distinction underscores the clinical reality that once a certain threshold of systemic inflammation is reached, the window for recovery may narrow, making the early identification of rising risk in the hypoinflammatory group a critical priority for clinical intervention.

Implications for Clinical Trial Design

To ensure the generalizability of these findings, the researchers conducted an extensive validation process involving 1,134 patients from the EDEN trial, various COVID-19 cohorts, and the RoCI registry. External validation across these cohorts confirmed the presence of heterogeneity and preserved non-linear probability-mortality patterns that were initially identified in the primary registry. This consistency across diverse patient populations suggests that the risk gradient within the hypoinflammatory group is a robust biological feature of acute hypoxemic respiratory failure rather than an artifact of a specific dataset. Furthermore, the study demonstrated that this prognostic insight is not limited to a single biomarker combination. Similar patterns of prognostic heterogeneity were observed when using a procalcitonin-based model, where procalcitonin (a peptide precursor of calcitonin used clinically to identify bacterial sepsis and systemic inflammation) served as the primary indicator. The fact that different inflammatory markers yield comparable results reinforces the clinical utility of moving toward continuous risk assessment. The clinical relevance of these findings centers on the potential to refine how physicians identify candidates for targeted therapies. Currently, binary classification systems may inadvertently exclude a significant number of patients who, despite being labeled as hypoinflammatory, carry a high risk of death. The researchers conclude that continuous probability-based stratification may identify additional trial-eligible high-risk patients and improve enrollment strategies for subphenotype-guided trials. By recognizing the 40% mortality risk present in the highest tertile of the hypoinflammatory group, clinicians can better appreciate the spectrum of critical illness. This approach allows for a more precise selection process in clinical trials, potentially capturing patients who would benefit from experimental interventions but are currently masked by traditional categorical thresholds. For the bedside clinician, these data suggest that a patient's inflammatory risk exists on a continuum, requiring a more nuanced interpretation of biomarkers to accurately predict prognosis and guide treatment escalation.

References

1. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky PM, workgroup TA. Acute renal failure – definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Critical Care. 2004. doi:10.1186/cc2872

2. Dellinger RP, Levy MM, Carlet J, et al. Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Medicine. 2007. doi:10.1007/s00134-007-0934-2

3. Hébert PC, Wells GA, Blajchman MA, et al. A Multicenter, Randomized, Controlled Clinical Trial of Transfusion Requirements in Critical Care. New England Journal of Medicine. 1999. doi:10.1056/nejm199902113400601

4. Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. 2010. doi:10.1136/bmj.c869

5. Page MJ, Moher D, Bossuyt PM, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021. doi:10.1136/bmj.n160

6. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. Clinical Infectious Diseases. 2007. doi:10.1086/511159